[go: up one dir, main page]

ECSP034871A - Composicion farmaceutica que comprende un inhibidor de lipasas y un ester de acido graso de sacarosa - Google Patents

Composicion farmaceutica que comprende un inhibidor de lipasas y un ester de acido graso de sacarosa

Info

Publication number
ECSP034871A
ECSP034871A EC2003004871A ECSP034871A ECSP034871A EC SP034871 A ECSP034871 A EC SP034871A EC 2003004871 A EC2003004871 A EC 2003004871A EC SP034871 A ECSP034871 A EC SP034871A EC SP034871 A ECSP034871 A EC SP034871A
Authority
EC
Ecuador
Prior art keywords
acid ester
pharmaceutical composition
sacarose
lipase inhibitor
composition including
Prior art date
Application number
EC2003004871A
Other languages
English (en)
Inventor
Marco Schroeder
Karsten Maeder
Rainer Eugen Martin
Susanne Raab
Lukas Christoph Scheibler
Thomas Schindler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP034871(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP034871A publication Critical patent/ECSP034871A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende un inhibidor de lipasas, preferiblemente orlistat, con un punto de fusión ³ 37°C, un éster de ácido graso de sacarosa en donde el éster de ácido graso de sacarosa es un mono-, di-, tri- o tetra-éster, y opcionalmente uno o más excipientes farmacéuticamente aceptables
EC2003004871A 2001-06-06 2003-12-01 Composicion farmaceutica que comprende un inhibidor de lipasas y un ester de acido graso de sacarosa ECSP034871A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01113793 2001-06-06

Publications (1)

Publication Number Publication Date
ECSP034871A true ECSP034871A (es) 2004-01-28

Family

ID=8177654

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004871A ECSP034871A (es) 2001-06-06 2003-12-01 Composicion farmaceutica que comprende un inhibidor de lipasas y un ester de acido graso de sacarosa

Country Status (39)

Country Link
US (4) US20030027786A1 (es)
EP (1) EP1399152B1 (es)
JP (2) JP4261337B2 (es)
KR (1) KR100753729B1 (es)
CN (1) CN1514725B (es)
AR (1) AR034355A1 (es)
AT (1) ATE356622T1 (es)
AU (1) AU2002257817B2 (es)
BG (1) BG66346B1 (es)
BR (1) BRPI0210266B1 (es)
CA (1) CA2448030C (es)
CO (1) CO5540293A2 (es)
CY (1) CY1107641T1 (es)
CZ (1) CZ299948B6 (es)
DE (1) DE60218845T2 (es)
DK (1) DK1399152T3 (es)
EC (1) ECSP034871A (es)
ES (1) ES2282415T3 (es)
GT (1) GT200200106A (es)
HR (1) HRP20030983B1 (es)
HU (1) HU230405B1 (es)
IL (2) IL158908A0 (es)
JO (1) JO2455B1 (es)
MA (1) MA27031A1 (es)
ME (1) ME00579B (es)
MX (1) MXPA03011191A (es)
MY (1) MY161871A (es)
NO (1) NO328006B1 (es)
NZ (1) NZ529630A (es)
PA (1) PA8546701A1 (es)
PE (1) PE20030230A1 (es)
PL (1) PL215266B1 (es)
PT (1) PT1399152E (es)
RS (1) RS50713B (es)
RU (1) RU2271808C2 (es)
SI (1) SI1399152T1 (es)
SK (1) SK287602B6 (es)
WO (1) WO2002098412A1 (es)
ZA (1) ZA200309007B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
FI20045076L (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
KR100910000B1 (ko) * 2005-05-13 2009-07-29 씨제이제일제당 (주) 리파아제 저해제 함유 약학 조성물
JP5044398B2 (ja) * 2005-06-09 2012-10-10 武田薬品工業株式会社 固形製剤
US20070111914A1 (en) * 2005-11-16 2007-05-17 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Environmentally friendly laundry method and kit
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
GB0618725D0 (en) * 2006-09-23 2006-11-01 Jagotec Ag Composition containing inhibitors of gastro-intestinal lipase
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
FR2994386B1 (fr) * 2012-08-07 2016-06-24 Thorel Jean-Noel Inhibition de l'adhesion de micro-organismes pathogenes par un ester de saccharose et/ou de sorbitan dans le traitement cosmetique de l'atopie cutanee
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
CN104546768B (zh) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法
JP7034078B2 (ja) 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体
CN113151373B (zh) * 2021-03-09 2023-07-04 武汉臻治生物科技有限公司 一种具有抗菌及抗肿瘤活性的蔗糖单酯的制备方法及其应用
KR102637596B1 (ko) 2022-03-18 2024-02-19 (주)보노보씨 기능성 목공교구

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1965133A1 (de) 1969-12-27 1971-07-22 Merck Patent Gmbh Verfahren zur Herstellung pharmazeutischer Zubereitungen
US4148924A (en) * 1977-06-13 1979-04-10 The Procter & Gamble Company Dermatological compositions
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
NL8600050A (nl) 1986-01-13 1987-08-03 Sanico Nv Farmaceutisch preparaat met vertraagde afgifte van het werkzame bestanddeel en werkwijze voor de bereiding er van.
EP0271963B1 (en) * 1986-12-19 1993-07-21 The Procter & Gamble Company Food compositions with superior blood cholesterol lowering properties
JP2748597B2 (ja) 1989-09-28 1998-05-06 三菱化学株式会社 食品劣化抑制剤
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
JP3112473B2 (ja) 1990-10-18 2000-11-27 オリンパス光学工業株式会社 屈折率分布型光学素子の製造方法
US5294451A (en) * 1991-03-29 1994-03-15 Curtice-Burns, Inc. Fat substitute compositions having reduced laxative effects
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
FR2735658B1 (fr) * 1995-06-21 1997-09-12 Capsulis Encapsulation de composes a usage alimentaire par des tensioactifs
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
TW401301B (en) * 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
KR20010079636A (ko) * 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 라이페이즈 저해제 및 키토산을 포함하는 약학 조성물
DK1105122T3 (da) * 1998-08-14 2005-08-08 Hoffmann La Roche Pharmaceutical compositions containing lipase inhibitors
AU1031500A (en) 1998-11-03 2000-05-22 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US6348492B1 (en) 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
AU1347701A (en) 1999-10-29 2001-05-14 John Jason Gentry Mullins Oxetanone derivatives
CA2411153C (en) * 2000-06-27 2007-01-30 Patrick Busson Method for preparing a composition
ES2240516T3 (es) * 2000-07-28 2005-10-16 F. Hoffmann-La Roche Ag Nuevo uso de los inhibidores de lipasa.
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6534097B1 (en) * 2002-07-11 2003-03-18 Betty Baggott Pest repellent

Also Published As

Publication number Publication date
US8039508B2 (en) 2011-10-18
AR034355A1 (es) 2004-02-18
CN1514725A (zh) 2004-07-21
SK16092003A3 (sk) 2004-05-04
RU2271808C2 (ru) 2006-03-20
SK287602B6 (sk) 2011-03-04
JP4261337B2 (ja) 2009-04-30
CZ20033525A3 (cs) 2004-04-14
CY1107641T1 (el) 2013-04-18
PL366890A1 (en) 2005-02-07
DE60218845D1 (de) 2007-04-26
PT1399152E (pt) 2007-06-05
BG66346B1 (bg) 2013-08-30
RS50713B (sr) 2010-06-30
CO5540293A2 (es) 2005-07-29
AU2002257817B2 (en) 2005-08-18
PA8546701A1 (es) 2003-01-24
IL158908A (en) 2008-08-07
EP1399152B1 (en) 2007-03-14
PE20030230A1 (es) 2003-03-17
WO2002098412A1 (en) 2002-12-12
NZ529630A (en) 2006-05-26
US8343543B2 (en) 2013-01-01
SI1399152T1 (sl) 2007-08-31
DE60218845T2 (de) 2008-01-03
ES2282415T3 (es) 2007-10-16
MA27031A1 (fr) 2004-12-20
US20030027786A1 (en) 2003-02-06
BR0210266A (pt) 2004-07-20
HUP0401208A3 (en) 2008-04-28
JP2004532271A (ja) 2004-10-21
JP2009108076A (ja) 2009-05-21
IL158908A0 (en) 2004-05-12
NO328006B1 (no) 2009-11-09
BG108421A (en) 2005-02-28
GT200200106A (es) 2003-02-11
HU230405B1 (hu) 2016-04-28
ME00579A (en) 2011-12-20
CA2448030A1 (en) 2002-12-12
US20130079391A1 (en) 2013-03-28
CZ299948B6 (cs) 2009-01-07
ATE356622T1 (de) 2007-04-15
MXPA03011191A (es) 2004-02-26
HUP0401208A2 (hu) 2004-11-29
ZA200309007B (en) 2005-04-26
RU2003136728A (ru) 2005-05-20
EP1399152A1 (en) 2004-03-24
DK1399152T3 (da) 2007-06-18
HRP20030983B1 (hr) 2011-10-31
US20050101562A1 (en) 2005-05-12
KR100753729B1 (ko) 2007-08-30
BRPI0210266B1 (pt) 2016-01-26
HRP20030983A2 (en) 2005-08-31
MY161871A (en) 2017-05-15
PL215266B1 (pl) 2013-11-29
CA2448030C (en) 2009-11-24
HK1067312A1 (zh) 2005-04-08
JO2455B1 (en) 2008-10-09
CN1514725B (zh) 2010-04-21
US20110301231A1 (en) 2011-12-08
ME00579B (me) 2011-12-20
KR20040010689A (ko) 2004-01-31
RS96003A (sr) 2006-10-27
NO20035318D0 (no) 2003-11-28

Similar Documents

Publication Publication Date Title
ECSP034871A (es) Composicion farmaceutica que comprende un inhibidor de lipasas y un ester de acido graso de sacarosa
AP2001002217A0 (en) 4-IODOPHENYLAMINO BENZHYDROXAMIC ACID OXYGENES ESTERS
DE60217103D1 (de) Verstärkte wirkung mehrfach ungesättigter fettsäuren
DK1087960T3 (da) Makrocykliske analoger og fremgangsmåder til deres anvendelse og fremstilling
BR0313876B1 (pt) uso de uma mistura, e, composições de combustível e de solvente
IL142535A0 (en) Pharmaceutical compositions for the treatment of inflammation
HUP0200917A3 (en) C7 ester substituted taxanes as antitumor agents and pharmaceutical compositions containing them
EP1455763A4 (en) FORMULATION OF ORAL ADMINISTRATION GELULA HAVING INCREASED PHYSICAL STABILITY
ES2191678T3 (es) Administracion transdermica del eutomero de un farmaco quiral.
MY127430A (en) Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols
EE200200628A (et) Dihüdroksüestrite ja nende derivaatide valmistamismeetod
ATE290046T1 (de) Weichmacher und urethan-härtbare zusammensetzung
ATE439362T1 (de) Ester in position 20 von camptothecinen
UY27321A1 (es) Nueva composición farmacéutica
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
ITMI20030063A1 (it) Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
ECSP045086A (es) Composiciones farmaceuticas que contienen macrolidos
AR040600A1 (es) Composicion farmaceutica estable que comprende eritropoietina
PE20050629A1 (es) PROFARMACO DE SULFONA DEL ACIDO 6-ß-HIDROXIMETILPENICILANICO COMO INHIBIDOR DE BETA-LACTAMASA
UY26337A1 (es) Formulaciones de lipidos solidos
CY1110814T1 (el) Νεα υποκατεστημενα αρυλοεξαδιενικα οξεα και εστερες αυτων τα οποια μπορουν να χρησιμοποιηθουν για την αγωγη και προληψη του διαβητη, δυσλιπιδαιμιας και αθηροσκληρωσης, φαρμακευτικες συνθεσεις που τα περιλαμβανουν και διεργασιες για την παρασκευη αυτων
ES2161898T3 (es) Utilizacion de al menos un acido graso contra la puesta de lepidopteros tortris.
ES2032225T3 (es) Procedimiento para la obtencion de n-metilbenzamida.
AR033503A1 (es) Un derivado de 3-metileno esteroide, una composicion farmaceutica que lo comprende, y uso de un derivado de 3-metileno esteroide
DE60209436D1 (de) Alkyl Ester der 2-(2-Fluorosulfonyl)-perfluoroethylenoxy-3-halogen-Propionsäure